Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
50%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Completed(1)

Detailed Status

Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

active_not_recruiting150%
completed150%

Recent Activity

1 active trials
Showing 2 of 2
active_not_recruitingnot_applicable

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

NCT01918683
completed

Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib

NCT01933945

Clinical Trials (2)

Showing 2 of 2 trials
NCT01918683Not Applicable

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

Active Not Recruiting
NCT01933945

Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib

Completed

All 2 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
2